孟鲁司特联合沙美特罗替卡松粉吸入剂治疗儿童咳嗽变异性哮喘疗效观察

Effect of Montelukast Combined with Seretide on Children with Cough Variant Asthma

目的:观察孟鲁司特联合沙美特罗替卡松粉吸入剂(舒利迭)治疗儿童咳嗽变异性哮喘的临床效果。方法:将100例咳嗽变异性哮喘患儿随机分为治疗组和对照组各50例。治疗组给予孟鲁司特联合沙美特罗替卡松粉吸入剂治疗,对照组则单用沙美特罗替卡松粉吸入剂治疗,疗程均为3个月,观察临床疗效并随访复发情况。结果:治疗组总有效率92.0%,高于对照组的76.0%(P<0.05);治疗组复发率4.0%,低于对照组的18.0%(P<0.05)。治疗后两组患儿最大呼气流速率(PEF)均明显改善,治疗组改善幅度大于对照组(P<0.01)。结论:孟鲁司特联合沙美特罗替卡松粉吸入剂治疗儿童咳嗽变异性哮喘,比单用沙美特罗替卡松粉吸入剂临床效果更好,能更快改善临床症状,且使用安全、复发率低,值得临床推广应用。

Objective： To observe the clinical effect of montelukast combined with salmeterol xinafoate and fluticasone propionate powder for inhalation （seretide） on children with cough variant asthma （CVA）. Methods： One hundred children with CVA were randomly divided into a treatment group and a control group with fifty cases each. Two groups were treated with seretide for three months, while the treatment group was added with montelukast. The clinical efficacy was evaluated after a period of treatment and follow- up the recurrence rate. Results： Total efficiency increased and recurrence rate decreased in the treatment group compared with the control group （P〈0.01）. The peak flow meter （PEF） in the two groups were improved significantly after treatment （P〈0.01） , and the PEF in the treatment group was higher than that in the control group after treatment （P〈0.01）. Conclusions： The clinical improvement appears more rapidly in treatment by montelukast combined with seretide than by seretide only. It is safe with low recurrence rate, and it is worthy of generalization.